Krystal Biotech, Inc. (NASDAQ:KRYS) Receives $220.00 Average PT from Analysts

Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) has received a consensus rating of "Buy" from the eight analysts that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $220.00.

KRYS has been the topic of several research analyst reports. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $215.00 price objective on shares of Krystal Biotech in a research note on Thursday, February 20th. HC Wainwright restated a "buy" rating and issued a $221.00 target price on shares of Krystal Biotech in a research report on Friday, February 28th. Chardan Capital upped their price target on shares of Krystal Biotech from $212.00 to $218.00 and gave the stock a "buy" rating in a report on Thursday, February 20th. Citigroup upped their target price on Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a report on Thursday, February 20th. Finally, Jefferies Financial Group began coverage on shares of Krystal Biotech in a research report on Wednesday, March 5th. They set a "buy" rating and a $245.00 target price on the stock.

Insider Activity

In related news, insider Suma Krishnan sold 25,000 shares of the firm's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the completion of the sale, the insider now owns 1,463,711 shares of the company's stock, valued at $260,233,178.69. This trade represents a 1.68 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Kathryn Romano sold 750 shares of the business's stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the transaction, the chief accounting officer now directly owns 12,604 shares in the company, valued at approximately $2,208,472.88. This trade represents a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 14.10% of the company's stock.

Remove Ads

Institutional Investors Weigh In On Krystal Biotech

Several hedge funds and other institutional investors have recently bought and sold shares of KRYS. US Bancorp DE increased its position in Krystal Biotech by 8.7% in the 4th quarter. US Bancorp DE now owns 1,027 shares of the company's stock valued at $161,000 after buying an additional 82 shares in the last quarter. Summit Investment Advisors Inc. lifted its holdings in shares of Krystal Biotech by 3.3% in the 4th quarter. Summit Investment Advisors Inc. now owns 2,595 shares of the company's stock worth $407,000 after purchasing an additional 82 shares in the last quarter. Fifth Third Bancorp grew its position in Krystal Biotech by 159.1% in the 1st quarter. Fifth Third Bancorp now owns 171 shares of the company's stock valued at $31,000 after purchasing an additional 105 shares during the period. Crossmark Global Holdings Inc. increased its stake in Krystal Biotech by 5.5% during the 4th quarter. Crossmark Global Holdings Inc. now owns 2,307 shares of the company's stock valued at $362,000 after purchasing an additional 121 shares in the last quarter. Finally, Envestnet Asset Management Inc. raised its holdings in Krystal Biotech by 1.1% during the fourth quarter. Envestnet Asset Management Inc. now owns 11,630 shares of the company's stock worth $1,822,000 after buying an additional 121 shares during the last quarter. 86.29% of the stock is owned by institutional investors.

Krystal Biotech Price Performance

NASDAQ:KRYS traded down $6.30 during trading hours on Friday, reaching $162.84. 10,633 shares of the company were exchanged, compared to its average volume of 293,969. The company has a market capitalization of $4.71 billion, a P/E ratio of 54.94 and a beta of 0.75. The business has a 50 day moving average of $174.25 and a 200 day moving average of $172.13. Krystal Biotech has a 1-year low of $141.72 and a 1-year high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings results on Monday, February 24th. The company reported $1.52 EPS for the quarter, beating analysts' consensus estimates of $1.29 by $0.23. The business had revenue of $91.10 million during the quarter, compared to the consensus estimate of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. Krystal Biotech's revenue for the quarter was up 116.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.30 earnings per share. As a group, equities research analysts anticipate that Krystal Biotech will post 6.14 earnings per share for the current fiscal year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).